Protection conferred by a recombinant Marek’s disease virus that expresses the spike protein from infectious bronchitis virus in specific pathogen-free chicken

Virology Journal

Xiufan Liu¹  Yezhen Huang¹  Yantao Wu¹  Xiaorong Zhang¹ 

[1] Laboratory of Animal Infectious Diseases, School of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, PR China

关键词: Marek’s disease virus;    Spike protein;    Infectious bronchitis virus;   

Others  :  1154765
DOI  :  10.1186/1743-422X-9-85

 received in 2011-10-09, accepted in 2012-05-04,  发布年份 2012

【 摘 要 】

Background

In many countries, the predominant field isolates of infectious bronchitis virus (IBV) have been classified as QX-like strains since 1996. However, no commercial vaccines that are specific for this type of IBV are currently available. Therefore, there is an urgent need to develop novel vaccines that prevent QX-like IBV infection.

Results

A recombinant Marek’s disease virus (MDV), rMDV-S1, that expresses the S1 subunit of the spike (S) protein from the QX-like infectious bronchitis virus (IBV) was constructed by inserting the IBV S1 gene into the genome of the CVI988/Rispens strain of MDV. Specific pathogen-free (SPF) chickens that were vaccinated with rMDV-S1 were protected when challenged with the QX-like IBV. They were observed to have mild clinical signs of disease, a short virus-shedding period and low mortality. Additionally, the rMDV-S1 conferred full protection to chickens against virulent MDV, as did the CVI988/Rispens strain.

Conclusions

Our results demonstrate that rMDV-S1 is an effective and promising recombinant vaccine for the prevention of QX-like IBV infection.

【 授权许可】

   
2012 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Saif YM, Barnes HJ, Fadly AM, Glisson JR, McDougald LR, Swayne DE: Diseases of poultry. 11th edition. Blackwell Pub. Professional, Ames, Iowa; 2008:101-119.
• [2]Stern DF, Burgess L, Sefton BM: Structural analysis of virion proteins of the avian coronavirus infectious bronchitis virus. Journal of virology 1982, 42:208-219.
• [3]Cavanagh D: Coronavirus avian infectious bronchitis virus. Veterinary research 2007, 38:281-297.
• [4]Sun C, Han Z, Ma H, Zhang Q, Yan B, Shao Y, Xu J, Kong X, Liu S: Phylogenetic analysis of infectious bronchitis coronaviruses newly isolated in China, and pathogenicity and evaluation of protection induced by Massachusetts serotype H120 vaccine against QX-like strains. Avian Pathol 2011, 40:43-54.
• [5]Han Z, Sun C, Yan B, Zhang X, Wang Y, Li C, Zhang Q, Ma Y, Shao Y, Liu Q, et al.: A 15-year analysis of molecular epidemiology of avian infectious bronchitis coronavirus in China. Infect Genet Evol 2011, 11:190-200.
• [6]Zou NL, Zhao FF, Wang YP, Liu P, Cao SJ, Wen XT, Huang Y: Genetic analysis revealed LX4 genotype strains of avian infectious bronchitis virus became predominant in recent years in Sichuan area, China. Virus genes 2010, 41:202-209.
• [7]Liu SW, Zhang QX, Chen JD, Han ZX, Liu X, Feng L, Shao YH, Rong JG, Kong XG, Tong GZ: Genetic diversity of avian infectious bronchitis coronavirus strains isolated in China between 1995 and 2004. Archives of virology 2006, 151:1133-1148.
• [8]Wang YD, Wang YL, Zhang ZC, Fan GC, Jiang YH, Liu XG, Ding J, Wang SS: Isolation and Identification of Glandular Stomach Type IBV ( QX IBV) in Chickens. Chinese Journal of Animal Quarantin 1998, 15:1-3.
• [9]Benyeda Z, Szeredi L, Mato T, Suveges T, Balka G, Abonyi-Toth Z, Rusvai M, Palya V: Comparative Histopathology and Immunohistochemistry of QX-like, Massachusetts and 793/B Serotypes of Infectious Bronchitis Virus Infection in Chickens. Journal of comparative pathology 2010, 143:276-283.
• [10]Benyeda Z, Mato T, Suveges T, Szabo E, Kardi V, Abonyi-Toth Z, Rusvai M, Palya V: Comparison of the pathogenicity of QX-like, M41 and 793/B infectious bronchitis strains from different pathological conditions. Avian Pathol 2009, 38:449-456.
• [11]Terregino C, Toffan A, Beato MS, De Nardi R, Vascellari M, Meini A, Ortali G, Mancin M, Capua I: Pathogenicity of a QX strain of infectious bronchitis virus in specific pathogen free and commercial broiler chickens, and evaluation of protection induced by a vaccination programme based on the Ma5 and 4/91 serotypes. Avian Pathol 2008, 37:487-493.
• [12]Monne I, Cattoli G, Jones R, Worthington K, Wijmenga W: QX genotypes of infectious bronchitis virus circulating in Europe. The Veterinary record 2008, 163:606-607.
• [13]Gough RE, Cox WJ, de Welchman BD, Worthington KJ, Jones RC: Chinese QX strain of infectious bronchitis virus isolated in the UK. The Veterinary record 2008, 162:99-100.
• [14]Beato MS, De Battisti C, Terregino C, Drago A, Capua I, Ortali G: Evidence of circulation of a Chinese strain of infectious bronchitis virus (QXIBV) in Italy. The Veterinary record 2005, 156:720.
• [15]Calnek BW: Pathogenesis of Marek’s disease virus infection. Curr Top Microbiol Immunol 2001, 255:25-55.
• [16]Davison AJ, Eberle R, Ehlers B, Hayward GS, McGeoch DJ, Minson AC, Pellett PE, Roizman B, Studdert MJ, Thiry E: The order Herpesvirales. Arch Virol 2009, 154:171-177.
• [17]Tsukamoto K, Kojima C, Komori Y, Tanimura N, Mase M, Yamaguchi S: Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek’s disease virus (MDV) with a recombinant MDV expressing IBDV VP2. Virology 1999, 257:352-362.
• [18]Martin MP, Wakenell PS, Woolcock P, O’Connor B: Evaluation of the effectiveness of two infectious bronchitis virus vaccine programs for preventing disease caused by a California IBV field isolate. Avian diseases 2007, 51:584-589.
• [19]Liu S, Zhang X, Wang Y, Li C, Liu Q, Han Z, Zhang Q, Kong X, Tong G: Evaluation of the protection conferred by commercial vaccines and attenuated heterologous isolates in China against the CK/CH/LDL/97I strain of infectious bronchitis coronavirus. Vet J 2007, 179:130-136.
• [20]Alvarado IR, Villegas P, El-Attrache J, Brown TP: Evaluation of the protection conferred by commercial vaccines against the California 99 isolate of infectious bronchitis virus. Avian diseases 2003, 47:1298-1304.
• [21]Jones RC, Worthington KJ, Capua I, Naylor CJ: Efficacy of live infectious bronchitis vaccines against a novel European genotype, Italy 02. The Veterinary record 2005, 156:646-647.
• [22]Liu S, Chen J, Han Z, Zhang Q, Shao Y, Kong X, Tong G: Infectious bronchitis virus: S1 gene characteristics of vaccines used in China and efficacy of vaccination against heterologous strains from China. Avian Pathol 2006, 35:394-399.
• [23]Liu S, Zhang X, Wang Y, Li C, Liu Q, Han Z, Zhang Q, Kong X, Tong G: Evaluation of the protection conferred by commercial vaccines and attenuated heterologous isolates in China against the CK/CH/LDL/97I strain of infectious bronchitis coronavirus. Vet J 2009, 179:130-136.
• [24]Geerligs HJ, Boelm GJ, Meinders CA, Stuurman BG, Symons J, Tarres-Call J, Bru T, Vila R, Mombarg M, Karaca K, et al.: Efficacy and safety of an attenuated live QX-like infectious bronchitis virus strain as a vaccine for chickens. Avian Pathol 2011, 40:93-102.
• [25]Lee HJ, Youn HN, Kwon JS, Lee YJ, Kim JH, Lee JB, Park SY, Choi IS, Song CS: Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain. Vaccine 2010, 28:2887-2894.
• [26]Arvidson Y, Tannock GA, Zerbes M, Ignjatovic J: Efficacy of Australian vaccines against recent isolates of avian infectious bronchitis viruses. Australian veterinary journal 1991, 68:211-212.
• [27]Al-Tarcha B, Sadoon SA: Cross-protection studies with vaccine strain H-120 of infectious bronchitis virus using ciliary activity. Acta veterinaria Hungarica 1991, 39:95-101.
• [28]Muneer MA, Newman JA, Halvorson DA, Sivanandan V, Nagaraja KV, Coon CN: Efficacy of infectious bronchitis virus vaccines against heterologous challenge. Research in veterinary science 1988, 45:22-27.
• [29]Liu S, Kong X: A new genotype of nephropathogenic infectious bronchitis virus circulating in vaccinated and non-vaccinated flocks in China. Avian Pathol 2004, 33:321-327.
• [30]Shi XM, Zhao Y, Gao HB, Jing Z, Wang M, Cui HY, Tong GZ, Wang YF: Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-gamma gene for immune protection against heterologous strains. Vaccine 2011, 29:1576-1582.
• [31]Chen HY, Yang MF, Cui BA, Cui P, Sheng M, Chen G, Wang SJ, Geng JW: Construction and immunogenicity of a recombinant fowlpox vaccine coexpressing S1 glycoprotein of infectious bronchitis virus and chicken IL-18. Vaccine 2010, 28:8112-8119.
• [32]Wang YF, Sun YK, Tian ZC, Shi XM, Tong GZ, Liu SW, Zhi HD, Kong XG, Wang M: Protection of chickens against infectious bronchitis by a recombinant fowlpox virus co-expressing IBV-S1 and chicken IFNgamma. Vaccine 2009, 27:7046-7052.
• [33]Swayne DE, Beck JR, Kinney N: Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian diseases 2000, 44:132-137.
• [34]Taylor J, Christensen L, Gettig R, Goebel J, Bouquet JF, Mickle TR, Paoletti E: Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge. Avian diseases 1996, 40:173-180.
• [35]Witter RL, Lee LF, Fadly AM: Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek’s disease virus. Avian diseases 1995, 39:269-284.
• [36]Li XQ, Wu YT, Xu XJ, Wang YY: Construction of a recombinant Marek’s disease virus expressing HA gene of H5 AIV. Chin J Vet Sci 2009, 29:1264-1268.
• [37]Morgan RW, Cantello JL, McDermott CH: Transfection of chicken embryo fibroblasts with Marek’s disease virus DNA. Avian diseases 1990, 34:345-351.
• [38]Geerligs H, Quanz S, Suurland B, Spijkers IE, Rodenberg J, Davelaar FG, Jongsma B, Kumar M: Efficacy and safety of cell associated vaccines against Marek’s disease virus grown in a continuous cell line from chickens. Vaccine 2008, 26:5595-5600.